Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Diwakar Davar
Study ID
NCT07223424
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • nivolumab — DRUG
    IV nivolumab (480mg Q4W), SC nivolumab (1200mg Q4W)
  • pembrolizumab — DRUG
    IV pembrolizumab (400mg Q6W) or SC pembrolizumab (790mg Q6W)

Study Details

The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

Key Dates

Start date
Nov 4, 2025
Status verified
Apr 2026
Primary completion
Nov 30, 2030
Completion
Nov 30, 2030

Study Design

Enrollment
880 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Subcutaneous to IV
    SC nivolumab (or pembrolizumab) x3 cycles followed by IV nivolumab (or pembrolizumab) x3 cycles.
  • Active Comparator: IV to Subcutaneous
    IV nivolumab (or pembrolizumab) x3 cycles followed by SC nivolumab (or pembrolizumab) x3 cycles

Primary Outcome Measure

Preference for Subcutaneous Nivolumab Treatment [ Time Frame: Up to 48 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UPMC Hillman Cancer CenterPittsburghPennsylvania15232
Danielle L Bednarz, RN
[email protected]
4126231191
Amy Rose, RN
[email protected]
4126478587
Diwakar J Davar, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Pittsburgh, PA

By condition
Cervical cancerEsophageal cancerLiver cancerMelanomaLung cancerKidney cancerSkin cancerUlcerative colitis
By specialty
OncologyGynecologic oncologyWomen's healthGI oncologyHepatologySkin cancerDermatologyLung oncologyLung diseaseUrologyGastroenterologyInflammatory bowel diseaseAutoimmune disease
By research site
UPMC Hillman Cancer Center· Pittsburgh, PA

Related Studies